Efficient Treg depletion induces T-cell infiltration and rejection of large tumors

European Journal of Immunology

Volumn 40, Issue 12, 2010, Pages 3325-3335

  Li, Xingrui ^a,b   Kostareli, Efterpi ^a   Suffner, Janine ^a   Garbi, Natalio ^a   Hämmerling, Günter J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Immunotherapy; Treg; Tumor immunology

Indexed keywords

CD4 ANTIBODY; CD8A ANTIBODY; DIPHTHERIA TOXIN; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PC 61; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR REJECTION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DIPHTHERIA TOXIN; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; TRANSGENES; TUMOR BURDEN;

EID: 78649557780     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041093     Document Type: Article

References (47)

1. Clemente, C. G., Mihm, M. C. Jr., Bufalino, R., Zurrida, S., Collini, P. and Cascinelli, N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996. 77: 1303-1310.
2. Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J. and Brady, M. S., Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 2007. 25: 869-875.
3. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B. et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005. 353: 2654-2666.
4. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M. et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006. 313: 1960-1964.
5. Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I., Kwappenberg, K. M., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. et al., High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007. 67: 354-361.
6. Gao, Q., Qiu, S. J., Fan, J., Zhou, J., Wang, X. Y., Xiao, Y. S., Xu, Y. et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007. 25: 2586-2593.
7. Lee, H. E., Chae, S. W., Lee, Y. J., Kim, M. A., Lee, H. S., Lee, B. L. and Kim, W. H., Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br. J. Cancer. 2008. 99: 1704-1711.
8. Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F. et al., CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 2007. 104: 3967-3972.
9. Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D. et al., Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008. 14: 28-36.
10. Jain, R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005. 307: 58-62.
11. Manzur, M., Hamzah, J. and Ganss, R., Modulation of the "blood-tumor" barrier improves immunotherapy. Cell Cycle 2008. 7: 2452-2455.
12. Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T. et al., Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008. 453: 410-414.
13. Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005. 6: 345-352.
14. Kim, J. Y., Kim, H. J., Hurt, E. M., Chen, X., Howard, O. M. and Farrar, W. L., Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem. Biophys. Res. Commun. 2007. 362: 44-50.
15. Wan, S., Xia, C. and Morel, L., IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 2007. 178: 271-279.
16. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C. et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001. 61: 4766-4772.
17. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A. et al., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002. 169: 2756-2761.
18. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
19. Hiraoka, N., Onozato, K., Kosuge, T. and Hirohashi, S., Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 2006. 12: 5423-5434.
20. Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006. 6: 295-307.
21. Valzasina, B., Piconese, S., Guiducci, C. and Colombo, M. P., Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006. 66: 4488-4495.
22. Zhou, G. and Levitsky, H. I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 2007. 178: 2155-2162.
23. Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q. et al., Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 2007. 178: 2883-2892.
24. North, R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 1063-1074.
25. Matsushita, N., Pilon-Thomas, S. A., Martin, L. M. and Riker, A. I., Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 2008. 333: 167-179.
26. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
27. Tanaka, H., Tanaka, J., Kjaergaard, J. and Shu, S., Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 2002. 25: 207-217.
28. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 3128-3133.
29. Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R. and Allison, J. P., Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 2008. 205: 2125-2138.
30. Pilon-Thomas, S., Mackay, A., Vohra, N. and Mule, J. J., Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 2010. 184: 3442-3449.
31. Suffner, J., Hochweller, K., Kuhnle, M. C., Li, X., Kroczek, R. A., Garbi, N. and Hammerling, G. J., Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J. Immunol. 2010. 184: 1810-1820.
32. Ganss, R., Ryschich, E., Klar, E., Arnold, B. and Hammerling, G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002. 62: 1462-1470.
33. Garbi, N., Arnold, B., Gordon, S., Hammerling, G. J. and Ganss, R., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 2004. 172: 5861-5869.
34. Thompson, E. D., Enriquez, H. L., Fu, Y. X. and Engelhard, V. H., Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 2010. 207: 1791-1804.
35. Cao, Y., Zhao, J., Yang, Z., Cai, Z., Zhang, B., Zhou, Y., Shen, G. X. et al., CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin. Immunol. 2010. 136: 21-29.
36. Powell, D. J., Jr., Attia, P., Ghetie, V., Schindler, J., Vitetta, E. S. and Rosenberg, S. A., Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J. Immunother. 2008. 31: 189-198.
37. Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K. and Clay, T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008. 112: 610-618.
38. Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 3623-3633.
39. Mahnke, K., Schonfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T. et al., Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007. 120: 2723-2733.
40. Bielekova, B., Howard, T., Packer, A. N., Richert, N., Blevins, G., Ohayon, J., Waldmann, T. A. et al., Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009. 66: 483-489.
41. Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E. and Carlson, N. G., Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007. 69: 785-789.
42. Waldmann, T. A., Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 2007. 27: 1-18.
43. Wiseman, L. R. and Faulds, D., Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999. 58: 1029-1042.
44. Gonzalez, E., Gutierrez, E., Hernandez, Y., Rosello, G., Gutierrez, M. J., Martinez, E. G., Manzanera, M. J. et al., Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function. Transplant Proc. 2005. 37: 3736-3737.
45. Rech, A. J. and Vonderheide, R. H., Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. NY Acad. Sci. 2009. 1174: 99-106.
46. Tomayko, M. M. and Reynolds, C. P., Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989. 24: 148-154.
47. Miloud, T., Henrich, C. and Hammerling, G. J., Quantitative comparison of click beetle and firefly luciferases for in vivo bioluminescence imaging. J. Biomed. Opt. 2007. 12: 054018.